Jones E H, Biggar R J, Nkrumah F K, Lawler S D
Hum Immunol. 1985 Jul;13(3):211-7. doi: 10.1016/0198-8859(85)90013-8.
Association between HLA-DR7 and Burkitt's lymphoma previously reported has been confirmed by a second study. Analysis of additional data from a second study of 33 Ghanaian patients with African Burkitt's lymphoma and 54 Ghanaian controls matched for age and ethnic origin showed that 39.4% of cases, but only 14.8% of controls, had HLA-DR7 (p less than 0.01). The relative risk of 3.7 is similar to that observed in the earlier study (3.3). Combining the earlier and present studies, analysis of clinical data from 94 patients with Burkitt's lymphoma and 116 controls shows the relative risk of Burkitt's lymphoma among individuals with HLA-DR7 was 3.4 (p less than 0.001). There was an increased relative risk of the disease associated with HLA-DR7 in: patients under 10 years of age; and patients with advanced stages of disease (Stage III or IV). However, comparison of relative risks by sequential analysis of 2 X 2 tables showed that these differences by age and stage were not statistically significant.
先前报告的HLA - DR7与伯基特淋巴瘤之间的关联已被另一项研究证实。对来自第二项研究的额外数据进行分析,该研究对33名患有非洲伯基特淋巴瘤的加纳患者和54名年龄及种族匹配的加纳对照进行了研究,结果显示39.4%的病例有HLA - DR7,而对照组只有14.8%有HLA - DR7(p小于0.01)。3.7的相对风险与早期研究中观察到的风险(3.3)相似。综合早期和当前的研究,对94名伯基特淋巴瘤患者和116名对照的临床数据进行分析表明,HLA - DR7个体患伯基特淋巴瘤的相对风险为3.4(p小于0.001)。在以下情况中,与HLA - DR7相关的疾病相对风险增加:10岁以下的患者;以及疾病晚期(III期或IV期)的患者。然而,通过对2×2表格进行序贯分析比较相对风险表明,这些按年龄和阶段划分的差异在统计学上并不显著。